Q1 2026 saw a significant revenue decline due to a lost major customer, but losses narrowed year-over-year. International expansion continues, with new distributor agreements and ongoing clinical studies supporting future growth.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.